Showing results (461-470 of 541) with videos related to
Sort By:
Pageof 55
Journal of Clinical Medicine|October 27, 2022
Cannabis Use Is Inversely Associated with Metabolic Disorders in Hepatitis C-Infected Patients (ANRS CO22 Hepather Cohort)Tangui Barré, Marc Bourlière, Clémence Ramier, et al.Diabetologia|December 15, 2015
Disruption of calcium transfer from ER to mitochondria links alterations of mitochondria-associated ER membrane integrity to hepatic insulin resistanceJennifer Rieusset, Jeremy Fauconnier, Melanie Paillard, et al.Cellular Microbiology|October 2, 2020
The CCCTC-binding factor CTCF represses hepatitis B virus enhancer I and regulates viral transcriptionValentina D'Arienzo, Jack Ferguson, Guillaume Giraud, et al.Gut|January 25, 2023
Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infectionHarry L A Janssen, Jinlin Hou, Tarik Asselah, et al.Hepatology (Baltimore, Md.)|May 13, 2011
Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological responseRoeland Zoutendijk, Jurriën G P Reijnders, Ashley Brown, et al.BMC Medicine|December 19, 2017
Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to eliminationVictor Virlogeux, Fabien Zoulim, Pascal Pugliese, et al.Cell Discovery|July 13, 2017
Metformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L antitumoral activitiesClaudio Pulito, Federica Mori, Andrea Sacconi, et al.Journal of Hepatology|October 26, 2021
Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosisAlessandro Loglio, Peter Ferenci, Sara Colonia Uceda Renteria, et al.Human Vaccines & Immunotherapeutics|August 3, 2019
Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trialFabien Zoulim, Claire Fournier, François Habersetzer, et al.Plos One|December 17, 2015
Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC StudyFrédégonde About, Tiphaine Oudot-Mellakh, Jonathan Niay, et al.Pageof 55